Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study
Open Access
- 14 May 2018
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 119 (5), 538-545
- https://doi.org/10.1038/s41416-018-0100-3
Abstract
To assess the safety profile, pharmacokinetics, pharmacodynamics and preliminary antitumour activity of fixed-dose SHR-1210, a novel anti-PD-1 antibody, in advanced solid tumours. A total of 36 patients with advanced solid tumours received intravenous SHR-1210 at 60 mg, 200 mg and 400 mg (4-week interval after first dose followed by a 2-week schedule) until disease progression or intolerable toxicity. The concentration of SHR-1210 was detected for pharmacokinetics, and receptor occupancy on circulating T lymphocytes was assessed for pharmacodynamics. No dose-limiting toxicities were observed. Maximum administered dose was not reached. Most adverse events were grade 1 or 2. Treatment-related severe adverse events were found in two patients. No treatment-related death was reported. Two complete responses (gastric cancer, bladder carcinoma) and seven partial responses were seen. In responders, the median follow-up time was 16.0 months (range 8.3–19.5), and the median duration of response was not reached (range 2.7–17.5+ months). The half-life of SHR-1210 was 2.94 d, 5.61 d and 11.0 d for 3 dose levels, respectively. Our results demonstrated a promising antitumour activity and a manageable safety profile of SHR-1210, displayed an explicit PK evidence of the feasibility of fixed dose, and established the foundation for further exploration.Keywords
This publication has 29 references indexed in Scilit:
- Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II StudyJournal of Clinical Oncology, 2017
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial CarcinomaThe New England Journal of Medicine, 2017
- The PD1:PD-L1/2 Pathway from Discovery to Clinical ImplementationFrontiers in Immunology, 2016
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2016
- A Guide to Rational Dosing of Monoclonal AntibodiesClinical Pharmacokinetics, 2012
- Fixed Dosing Versus Body Size—Based Dosing of Therapeutic Peptides and Proteins in AdultsThe Journal of Clinical Pharmacology, 2012
- Fixed Dosing Versus Body Size—Based Dosing of Monoclonal Antibodies in Adult Clinical TrialsThe Journal of Clinical Pharmacology, 2009
- Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasionNature Medicine, 2002
- Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte ActivationThe Journal of Experimental Medicine, 2000
- B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretionNature Medicine, 1999